AnaptysBio, Inc. (ANAB) Stock Price & Analysis
AnaptysBio, Inc. (ANAB) closed at USD 48.1 on Thursday, October 22, 2026, up 0.33% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 47.94; the Oct 22, 2026 session ranged USD 46.83–48.51 on volume of 254,904 shares. Market capitalization is $1.44B, with a 52-week range of USD 20.18–72.36 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:48 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ANAB.md
Key facts (ANAB)
- Last four reported quarters (through Mar 31, 2026): revenue $232M, net income -$26.8M (-11.5% margin), free cash flow $4.4M (SEC filings).
- Earnings quality: non-operating income -$71.1M vs operating income $220M over the last four quarters; P/E excluding non-operating income ≈32.7x (estimate: non-operating income taxed at the company's 0.5% effective rate).
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $249K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.63 on a 1–5 scale) (8 analysts), mean target USD 87.25 (range 60–140).
- Total return with dividends: 1Y +112.2% vs S&P 500 +14.9%; 5Y +152.7% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 0.8, revenue estimate $33.5M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ANAB)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $63.2M | $10.3M | $17.2M | $91.3M | $235M | $232M |
| Operating income | -$56.8M | -$115M | -$164M | $66.2M | $227M | $220M |
| Net income | -$57.8M | -$129M | -$164M | -$145M | -$13.2M | -$26.8M |
| EPS (diluted) | -$1.41 | -$3.05 | -$4.05 | -$4.92 | -$0.44 | — |
| Free cash flow | -$47.3M | -$74.0M | -$122M | -$136M | $19.6M | $4.4M |
| Operating margin | -89.9% | -1119.4% | -958.3% | 72.5% | 96.7% | 94.6% |
| Net margin | -91.5% | -1251.3% | -953.7% | -159.1% | -5.6% | -11.5% |
| Revenue growth | -15.8% | -83.7% | +66.8% | +432.0% | +157.0% | — |
| Cash + short-term investments | $548M | $441M | $391M | $285M | $212M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Mar 31, 2026) (ANAB)
P/E ex non-operating (est.) ≈32.7x · P/S 6.2x · P/FCF 326.1x · P/B 112.8x · FCF yield 0.31% · Earnings yield -1.86% · Buyback yield (TTM) 4.46%
Insider sales (SEC Form 4, open-market, last ~7 months) (ANAB)
1 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Renton Hollings | Director | 5,000 | $249K | 31.3% | Yes (adopted March 30, 2026) | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (ANAB)
Consensus Buy (mean 1.63 on a 1–5 scale), 8 analysts; mean target USD 87.25 (low 60, high 140).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-30 | JP Morgan | Target lowered | Overweight | $70 → $60 |
| 2026-09-24 | HC Wainwright & Co. | Reiterated | Buy | $95 |
| 2026-09-23 | Leerink Partners | Target lowered | Outperform | $90 → $81 |
| 2026-08-25 | TD Cowen | Target lowered | Buy | $75 → $70 |
| 2026-08-24 | HC Wainwright & Co. | Reiterated | Buy | $95 |
Total return (dividends reinvested) (ANAB)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +112.2% | +152.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +112.8% | +20.3% |
| Volatility (annualized) | 63.0% | 65.2% |
| Max drawdown | -34.9% (Jul 2026→Oct 2026) | -67.7% (Sep 2024→Dec 2024) |
ANAB revenue by business segment (quarter ended Mar 31, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Royalty Management Company | $25.6M | 100.0% | -8.0% |
| Total revenue | $25.6M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
ANAB suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Vanda Pharmaceuticals Inc. (VNDA) | “We also discovered and out-licensed, in financial collaborations, multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli (dostarlimab-gxly) or "Jemperli") to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals Inc. ("Vanda").” |
| Partner | TESARO | “In March 2014, we entered into a Collaboration and Exclusive License Agreement (the "GSK Agreement") with TESARO, Inc. ("Tesaro"), an oncology-focused biopharmaceutical company now a part of GSK (Tesaro and GSK are hereinafter referred to, collectively, as "GSK").” |
| Partner | MYRIAD GENETICS INC (MYGN) | “Myriad Genetics, Inc., BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig., Mayo Collaborative Services v.” |
| Partner | TD Cowen and Leerink Partners | “In August 2024, we entered into an underwriting agreement with TD Cowen and Leerink Partners LLC as representatives to the several underwriters listed therein (the "Underwriters"), pursuant to which we issued and sold an aggregate of 2,750,498 shares of our common stock to the Underwriters, at an offering price of $36.50 per share.” |
| Partner | LLC and Leerink Partners | “In August 2024, we entered into an underwriting agreement with TD Securities (USA) LLC and Leerink Partners LLC as representatives to the several underwriters listed therein (the "Underwriters"), pursuant to which we issued and sold an aggregate of 2,750,498 shares of our common stock to the Underwriters, at an offering price of $36.50 per share.” |
Quoted from the company's 10-K filed Mar 3, 2026.
Companies that name ANAB in their SEC reports
| Relationship to ANAB | Company | Filing | Sentence |
|---|---|---|---|
| partner | Vanda Pharmaceuticals Inc. (VNDA) | 10-K Feb 12, 2026 | “In January 2025, we entered into an exclusive global license agreement with AnaptysBio, Inc. (Anaptys) under which we acquired the worldwide rights to develop, manufacture and commercialize imsidolimab.” |
ANAB company outlook (results filed May 12, 2026)
- “Converted from GBP to USD using Q3 2025 average exchange rate (1.35x) 3. ~$275 million accrued to Sagard through Q1 2026 and assumes a ~10% quarter-over-quarter growth rate for Jemperli from Q4'25 through Q2'27 and milestone payments associated with filing ($5mm) and approval ($10mm) of dMMR rectal approval in the EU AnaptysBio, Inc.”
Quoted word-for-word from the SEC 8-K results press release.
ANAB analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.80 | $0.38 | +107.2% | $33.5M | 2 |
| Next quarter (ends Dec 2026) | $1.54 | $0.73 | +111.6% | $52.4M | 2 |
| Current fiscal year (ends Dec 2026) | $4.35 | $-0.23 | -1985.5% | $101.1M | 3 |
| Next fiscal year (ends Dec 2027) | $5.07 | $5.24 | -3.2% | $171.3M | 4 |
ANAB options: expected move
Options price a move of about ±20.9% (±$10.05) by Nov 20, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±7.7% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 90.2% | ±20.9% |
| Dec 18, 2026 | 56 | 90.9% | ±29.2% |
| Feb 19, 2027 | 119 | 81.2% | ±37.4% |
| May 21, 2027 | 210 | 73.8% | ±44.7% |
30-day implied volatility 93.9% vs 47.7% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:48 UTC)
| Price | USD 48.1 |
|---|---|
| Change | ▲ 0.33% (up) |
| Previous Close | USD 47.94 |
| Open | USD 47.65 |
| Day Range | USD 46.83 – 48.51 |
| 52-Week Range | USD 20.18 – 72.36 |
| Volume | 254,904 shares |
| Market Cap | $1.44B |
| Exchange | NMS |
Technical Analysis (ANAB)
Nexqual's technical model rates ANAB "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 09:48 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.13 (neutral) |
| vs SMA50 | Below (USD 52.85) |
| MACD | -1.54 (negative) |
Analyst Ratings (ANAB)
Wall Street analysts rate ANAB "Buy" based on 8 analysts, with a mean price target of USD 87.25 (range USD 60–140), per Nexqual as of October 23, 2026 at 09:48 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 87.25 |
| High Target | USD 140 |
| Low Target | USD 60 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (ANAB)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD 0.8 |
| Revenue Estimate | $33.46M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 4.93 vs est 0.14 ▲ beat |
| 2025-12-31 | USD 1.58 vs est 0.93 ▲ beat |
| 2025-09-30 | USD 0.52 vs est -1.25 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Financials & Fundamentals (ANAB)
| Total Revenue | $106.09M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +23.50% |
| Gross Margin | +105.03% |
| Operating Margin | +53.38% |
| Profit Margin | +246.96% |
| Debt / Equity | 25.47 |
| Current Ratio | 5.61 |
| Total Cash | $164.14M |
| Total Debt | $269.59M |
| Free Cash Flow (last four quarters to Mar 2026, SEC 10-Q / 10-K) | $4.41M (1.9% of revenue) |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Financial Health Score (ANAB)
Nexqual rates AnaptysBio, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:48 UTC.
| Growth | Strong — Revenue +157% YoY (annual) |
|---|---|
| Profitability | Strong — Operating margin 53% |
| Balance Sheet | Weak — $164M cash vs $270M debt |
| Cash Flow | Mixed — FCF $4M (last 4 quarters to Mar 2026, SEC), slim 1.9% margin |
| Efficiency | Mixed — No data |
Ownership (ANAB)
| Insider Ownership | +5.63% |
|---|---|
| Institutional Ownership | +105.41% |
| Shares Outstanding | 29.90M |
| Float | 20.44M |
| Short % of Float | +38.53% |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Leadership (ANAB)
AnaptysBio, Inc. is led by Daniel R. Faga, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:48 UTC.
| President, CEO & Director | Daniel R. Faga |
|---|---|
| Chief Financial Officer | Christopher M. Murphy |
| Senior Vice President of Human Resources | Beth Mueller |
Major Backers & Investors (ANAB)
Notable institutional backers of AnaptysBio, Inc. include EcoR1 Capital, LLC, Tang Capital Management, LLC, Affinity Asset Advisors, Llc, according to Nexqual as of October 23, 2026 at 09:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| EcoR1 Capital, LLC | 26.36% |
| Tang Capital Management, LLC | 4.45% |
| Affinity Asset Advisors, Llc | 2.76% |
| Sanofi | 2.75% |
| Millennium Management | 2.7% |
| Woodline Partners LP | 2.4% |
| 683 Capital Management LLC | 2.21% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.17% |
| State Street | 4.3% |
| Vanguard Group | 3.03% |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
From AnaptysBio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- Under the GSK Agreement, a Biologics License Application ("BLA") for our most advanced partnered program, which is a PD-1 antagonist antibody called Jemperli (dostarlimab), was approved by the FDA in April 2021 for the treatment of advanced or recurrent deficient mismatch repair endometrial cancer ("dMMREC").
- In total, our patent portfolio, including patents co-owned with GSK, patents licensed from Centessa Pharmaceuticals (UK) Ltd. ("Centessa"), and patents to certain antibody discovery technology consisted of approximately 96 issued patents and 120 pending patent applications as of December 31, 2025.
- Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.
- We believe that our approach to antibody design allows us to effectively tailor antibodies to achieve a unique therapeutic benefit.
Partnerships
- We currently recognize revenue from milestones and royalties achieved under our immuno-oncology collaboration with GSK and license and transition services revenue from our collaboration with Vanda.
- Our collaborations include an immuno-oncology-focused collaboration with GSK.
Legal & Regulatory Risks (Item 1A, quoted)
- Our ongoing and planned clinical trials or those of our collaborators may reveal significant adverse events, toxicities or other side effects and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.
- We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, required regulatory approvals in the United States or in foreign jurisdictions, which would materially impair our ability to commercialize and generate revenue from our product candidates.
- Any drugs we develop may become subject to unfavorable third party reimbursement practices and pricing regulations.
- Our relationships with customers and third party payors will be subject to applicable anti-kickback, fraud and abuse, transparency and other health care laws and regulations, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:48 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt